NASDAQ · PYPD
PolyPid Ltd.
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
Loading market information…
NASDAQ · DYAI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Dyadic International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Dyadic International, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dyadic International, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 14, 2025 | -$0.07 | $393.57K |
|---|
| Q4 2024 | Mar 26, 2025 | -$0.05-25.0% vs estimate | $817.38K-48.91% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.01+85.71% vs estimate | $1.96M+22.34% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
$1.49+$0.07 (+4.56%)
RenovoRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.47% below the high.
$1.02$0.00 (0.0%)
Annovis Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.45% below the high.
$2.23-$0.04 (-1.76%)
Veru Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.58% below the high.
$2.23+$0.06 (+2.93%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 62.08% below the high.
$0.81-$0.03 (-3.13%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
